These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 28506090

  • 1. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK, Hannan TJ, Janetka JW.
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [Abstract] [Full Text] [Related]

  • 2. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK, Cusumano ZT, Janetka JW.
    Expert Opin Ther Pat; 2016 Jul; 26(2):175-97. PubMed ID: 26651364
    [Abstract] [Full Text] [Related]

  • 3. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.
    Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, Lüdin N, Bezençon J, Schwardt O, Maier T, Ernst B.
    J Med Chem; 2015 Mar 12; 58(5):2221-39. PubMed ID: 25666045
    [Abstract] [Full Text] [Related]

  • 4. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C, Han Z, Kalas V, Klein R, Pinkner JS, Ford B, Binkley J, Cusumano CK, Cusumano Z, Mydock-McGrane L, Hultgren SJ, Janetka JW.
    ChemMedChem; 2016 Feb 17; 11(4):367-73. PubMed ID: 26812660
    [Abstract] [Full Text] [Related]

  • 5. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
    Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.
    J Med Chem; 2010 Dec 23; 53(24):8627-41. PubMed ID: 21105658
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists.
    Schwardt O, Rabbani S, Hartmann M, Abgottspon D, Wittwer M, Kleeb S, Zalewski A, Smieško M, Cutting B, Ernst B.
    Bioorg Med Chem; 2011 Nov 01; 19(21):6454-73. PubMed ID: 21962988
    [Abstract] [Full Text] [Related]

  • 7. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.
    Sivignon A, Yan X, Alvarez Dorta D, Bonnet R, Bouckaert J, Fleury E, Bernard J, Gouin SG, Darfeuille-Michaud A, Barnich N.
    mBio; 2015 Nov 17; 6(6):e01298-15. PubMed ID: 26578673
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ.
    Nature; 2017 Jun 22; 546(7659):528-532. PubMed ID: 28614296
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren SJ.
    mBio; 2015 Jun 30; 6(4):e00820. PubMed ID: 26126855
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H.
    Mol Microbiol; 2005 Jan 30; 55(2):441-55. PubMed ID: 15659162
    [Abstract] [Full Text] [Related]

  • 17. Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections.
    Mydock-McGrane L, Cusumano Z, Han Z, Binkley J, Kostakioti M, Hannan T, Pinkner JS, Klein R, Kalas V, Crowley J, Rath NP, Hultgren SJ, Janetka JW.
    J Med Chem; 2016 Oct 27; 59(20):9390-9408. PubMed ID: 27689912
    [Abstract] [Full Text] [Related]

  • 18. Structure-based drug design and optimization of mannoside bacterial FimH antagonists.
    Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW.
    J Med Chem; 2010 Jun 24; 53(12):4779-92. PubMed ID: 20507142
    [Abstract] [Full Text] [Related]

  • 19. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.
    Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ.
    Antimicrob Agents Chemother; 2012 Sep 24; 56(9):4738-45. PubMed ID: 22733070
    [Abstract] [Full Text] [Related]

  • 20. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M, Abgottspon D, Cicek E, Jiang X, Schwardt O, Rabbani S, Ernst B.
    Assay Drug Dev Technol; 2011 Oct 24; 9(5):455-64. PubMed ID: 21675870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.